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Abstract
Trypanosoma brucei cyclic nucleotide phosphodiesterase B1 (TbrPDEB1) and TbrPDEB2 have
recently been validated as new therapeutic targets for human African Trypanosomiasis by both
genetic and pharmacological means. In this study we report the crystal structure of the catalytic
domain of the unliganded TbrPDEB1 and its use for the in silico screening for new TbrPDEB1
inhibitors with novel scaffolds. The TbrPDEB1 crystal structure shows the characteristic folds of
human PDE enzymes, but also contains the parasite-specific P-pocket found in the structures of
Leishmania major PDEB1 and Trypanosoma cruzi PDEC. The unliganded TbrPDEB1 X-ray
structure was subjected to a structure-based in silico screening approach that combines molecular
docking simulations with a protein-ligand interaction fingerprint (IFP) scoring method. This
approach identified, six novel TbrPDEB1 inhibitors with IC50 values of 10–80 μM, which may be
further optimized as potential selective TbrPDEB inhibitors.
INTRODUCTION
Human African Trypanomiasis (HAT), also known as African sleeping sickness, is a deadly
infectious disease caused by the kinetoplastid Trypanosoma brucei (Tbr). The Trypanosoma
brucei genome encodes five cyclic nucleotide phosphodiesterases (PDEs), of which
TbrPDEB1 and TbrPDEB2 were recently validated as potential new drug targets for the
treatment of HAT.1–4 Both TbrPDEB enzymes selectively catalyze the hydrolysis of cAMP
to AMP. In a dual knock-down RNAi study, Seebeck and colleagues reported that
simultaneous RNA knockdown of both TbrPDEB1 and TbrPDEB2 results in impaired
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division of trypanosomes and eventual death of the parasites.5 These studies have
subsequently been confirmed by pharmacological targeting of TbrPDEB1 and
TbrPDEB2,1–2, 6 suggesting that drug repurposing efforts and/or tapping into the wealth of
knowledge around cyclic nucleotide PDEs (e.g.150 published crystal structures and over
3000 published submicromolar PDE inhibitors)7–8 might be an effective way to find new
HAT treatments. Initial drug profiling and preliminary medicinal chemistry suggests that the
human PDE inhibitors could be used as interesting starting scaffolds for the discovery of
TbrPDEB inhibitors.1–2, 9 Using a computational design and fragment merging approach,
we recently reported pyrazolinones VUF118512 (1, Figure 1) and VUF135242 (2, Figure 1)
as TbrPDEB1 inhibitors. The hPDE4 inhibitor PPS540196 (3, Figure 1) was discovered in a
high throughput screening of a proprietary library of 400,000 compounds by Nycomed
Pharma. This PDE inhibitor is currently the most potent TbrPDEB1 inhibitor, and shows
substantial in vitro trypanocidal activity. Three SAR studies starting from known hPDE
inhibitors have resulted in the discovery of TbrPDEB1 inhibitors, among which piclamilast1
(4, Figure 1) was the most successful.1, 10–11 The TbrPDEB1 inhibitor, 1-(3-(4-
hydroxybutoxy)-4-methoxyphenyl)-3-methylbutan-1-one9 (5, Figure 1) was originally
discovered as an inhibitor of Leishmania major PDEB1 (LmjPDEB1) through structure-
based design, but also appears to inhibit TbrPDEB1 to some extent.
While human PDE inhibitors may provide important starting points for the discovery of
novel TbrPDEB1 inhibitors, it has proven challenging to achieve parasite-selective PDE
inhibition. This lack of selectivity could be a major hurdle in the development of TbrPDEB1
inhibitors as HAT drugs. To resolve this issue, we have initiated a structural biology and
structure-based design program to guide the discovery of selective TbrPDEB1 inhibitors.
In this study we present for the first time a crystal structure (4I15) of the unliganded
catalytic domain of the TbrPDEB1 enzyme. A parasite-specific pocket (P-pocket), first
observed in the LmjPDEB1 crystal structure (2R8Q)12 and subsequently seen in TcrPDEC
structures (3V93 and 3V94)4, is also present in the new TbrPDEB1 crystal structure. The
high resolution crystal structure of the catalytic domain of TbrPDEB1 has been employed in
a structure-based virtual screen, aiming at the identification of new TbrPDEB1 inhibitors.
Virtual screening remains underutilized in the search for PDE inhibitors as shown by the
fact that only three prospective structure-based virtual screening studies have been reported
to date.13–15 One of these was performed using a homology model of Trypanosoma cruzi
PDEC (TcrPDEC).13 In the present study we report the use of the newly resolved X-ray
structure of the TbrPDEB1 catalytic domain in a customized virtual screening campaign,
which lead to the identification of new TbrPDEB1 inhibitors.
RESULTS AND DISCUSSION
Unliganded TbrPDEB1 crystal structure
The full length TbrPDEB1 enzyme contains two GAF domains (residues D234 - E554) and
a catalytic domain (residues V586 – R908).3 The GAF domains have been shown to bind
cAMP, but only the catalytic domain is able to hydrolyse cAMP to AMP.16 Inhibition of the
isolated catalytic domain and the full length enzyme by recently identified TbrPDEB1
inhibitors occurs at similar inhibitor concentrations.2 The catalytic domain (residues 576–
918) of TbrPDEB1, expressed and purified from Escherichia coli, was used in our studies.
Following crystallization, the TbrPDEB1 structure with residues 586–918 could be resolved
by X-ray diffraction at a resolution of 1.65 Å (Table 1). The catalytic domain comprises 16
α-helices, 7 310-helices and no β-strands (Figure 2A). Two divalent metal atoms are present
which have been designated zinc and magnesium in accordance with common PDE metal
ligation without further verification. The metal ions each form an octahedral geometry; zinc
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coordinates H673, H709, D710, D822 and two water molecules, while magnesium
coordinates D710 and five water molecules. The TbrPDEB1 X-ray structure shows the
presence of the parasite-specific P-pocket, which is formed with the invariant Q874 on H15
and the M-loop (Figure 2C) on opposing sides, and is adjacent to the substrate binding
pocket.
The structural superposition of TbrPDEB1 with LmjPDEB1 (2R8Q),12 TcrPDEC (3V94)4
and hPDE4B (1XM4)17 yielded RMSDs of 0.86 Å, 1.78 Å and 1.61 Å respectively for
comparable Cα atoms (Figure 2B), indicating high overall structural similarity. Taking a
closer look at the region between the Q874 and the M-loop it is clear that the P-pockets of
TbrPDEB1 and LmjPDEB1 overlap well. However, the P-pocket of TcrPDEC is displaced
by about 5 Å, and hPDE4B does not have a P-pocket12 (Figure 2C–F). These structural
differences can be explained by sequence differences in H14, H15, and the M-loop. A key
difference seems to be residue T841 (L539 TcrPDEC) and T841 (M411 hPDE4) in H14.
The conformation of the M-loop also plays a role in the appearance of the P-pocket. This
conformation is influenced by the length of the M-loop which is two residues shorter in
TcrPDEC and one in hPDE4, when compared to the TbrPDEB1 and LmjPDEB1 M-loops.
The secondary structure elements of TbrPDEB1 and LmjPDEB1 are also almost identical,
whereas those of TcrPDEC and hPDE4B deviate significantly (Figure 3). Comparing the
residues of the substrate binding pocket, the only difference between TbrPDEB1 and
LmjPDEB1 is to I823 (V836 LmjPDEB1) and superposing the pocket Cα atoms results in
an RMSD of 0.40 Å. In the case of TcrPDEC, the residues that are different are; N825
(A524 TcrPDEC), V826 (S525), S833 (A532), A837 (L536), V840 (I538), T841 (L539),
Y845 (A543), M861 (G559) and W911 (Y606), the RMSD of the pocket residues is 1.03 Å.
For hPDE4B, the substrate binding pocket residues that are different are; I823 (L393
hPDE4B), V826 (P396), S833 (Y403), A837 (T407), V840 (I410), T841 (M411) and W911
(Y480), comparing the pocket residues results in a lower RMSD of 0.74 Å. These data are in
line with the percentage of residue identity between the catalytic domains of TbrPDEB1 and
LmjPDEB1 (66%), TbrPDEB1 and TcrPDEC (21%), and TbrPDEB1 and hPDE4B (27%).
Moreover, the full length TcrPDEC does not contain GAF domains and has been shown to
have a dual specificity for cAMP and cGMP, further indicating its evolutionary distance
from TbrPDEB1.4, 13, 18 The high sequence identity of TbrPDEB1 and LmjPDEB1 on the
other hand, suggests that a single compound may well inhibit both parasite PDEs and might
be useful against both kinetoplastids.
The crystallographic asymmetric unit contains two molecules of TbrPDEB1 that form a
dimer in the crystal lattice. Molecule B is involved in further crystal lattice contacts which
close off part of the active site from bulk solvent. However, as only one of the two chains is
involved in formation of these crystallographic lattice contacts, we suggest that this is likely
to represent a crystallographic artifact without biological relevance. Superposition of the Cα
atoms of the A and B chains of the asymmetric unit with MOE (Molecular Operating
Environment version 2011.10)19 resulted in an RMSD of 0.49 Å. The only significant
rotamer deviation seen in the pocket residues is an 86° rotation of V840. The overall
similarity between the A and B chains indicates that the observed lattice contacts have little
influence on the conformation of the protein.
The substrate binding pocket of the unliganded structure contains two well defined water
networks, one surrounding the invariant glutamine (Q874) and the other surrounding the
metal ions (Figure 4). Analysis of published PDE crystal structures containing inhibitors
revealed that in all cases several of the water molecules surrounding Q874 are displaced,
most often to allow the formation of hydrogen bonds between Q874 and the bound ligand.
The water molecules surrounding the metal ions are coordinated tightly and only three
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inhibitors; an2898 in hPDE4B (3O0J), rolipram in hPDE4B2B (1RO6) and zardaverine in
hPDE4D (1XOR), and the substrate products AMP and GMP displace some of them. A
further feature of PDE inhibitor binding is the occupation of the hydrophobic clamp, the
space between F877 and V840, which is invariably occupied by an aromatic or highly
conjugated ring system. In the TbrPDEB1 crystal structure the B-factor of the M-loop
residues is high in comparison to the other residues in the structure, reflecting the flexibility
of this loop. The conformation of the M-loop is stabilized by the π-stacking of F862 against
F844 (Figure 4), as shown by F862 having a lower B-factor than other residues in the M-
loop. The parasite-specific P-pocket forms a pore through the protein between Q874 and
Y845. Although inhibitors have not been shown to occupy this region in crystal structures,
in silico modeling suggests that the occupation of this region may result in selective
TbrPDEB1 inhibitors.2
Structure-based virtual screening
We have performed a prospective structure-based virtual screening study, evaluating both
the new TbrPDEB1 crystal structure and the customized virtual screening method, for the
computer-aided discovery of novel TbrPDEB1 inhibitors. We used a protocol that combines
a docking scoring function (PLANTS20) with a protein-ligand interaction fingerprint (IFP21)
scoring method to rank molecular docking poses of 385,000 commercially available
molecules (Figure 5). The IFP scoring method determines ligand binding mode similarity
using interaction types (negatively and positively charged, H-bond acceptor and donor,
aromatic face-to-edge and face-to-face, and hydrophobic) encoded as bits for each pocket
residue (Figure 6). A Tanimoto coefficient measuring IFP similarity to a reference ligand
pose (derived from a computationally predicted protein-ligand binding mode in this case) is
used to score the docking poses of a large database of compounds, in an approach similar to
that used to successfully discover several novel histamine H1 receptor ligands with a high
virtual screening hit rate of 73%.22 The in silico predicted binding modes of compounds 1
and 2 in the unliganded TbrPDEB1 structure (Figure 6A–B) were used to define reference
IFPs. These were used to select PLANTS docking poses in the prospective structure-based
virtual screening study for novel TbrPDEB1 inhibitors.
Figure 5 gives an overview of the virtual screening steps (I–III) and the hit selection routes
(A–D). Consecutive virtual filters of increasing complexity are applied throughout the
virtual screening process. These facilitate the selection of a small number of compounds
from a large compound collection, while at the same time allowing the identification of
novel chemotypes. Starting with 7.5 million unique compounds from 14 suppliers in the
ZINC database23 (step I), physicochemical property filters and substructure filters were
applied, reducing the number to 385,000 molecules (Step II). The physicochemical filters
were defined using the properties of 3192 known PDE inhibitors with IC50 values below 10
μM, retrieved from the ChEMBL database as a reference.8 The total polar surface area
(TPSA) and LogP filter values were adjusted to select compounds more likely to penetrate
the blood brain barrier.24 The substructure filter (Supporting Information: Figure S2) was
defined following the analysis of 132 PDE crystal structures. These indicated that the
presence of an aromatic or conjugated ring system, which contains (or is connected to) a
hydrogen bond acceptor moiety, is found in all co-crystalized ligands. This substructure
ensures binding of the inhibitors to the hydrophobic clamp (between F877 and V840 in
TbrPDEB1) while forming an essential hydrogen bond (present in 92% of the 132 PDE
crystal structures) with an invariant glutamine (Q874 in TbrPDEB1).
The 385,000 molecules were docked into the TbrPDEB1 crystal structure using PLANTS
protein-ligand docking software (step III).20 Of these, 64,000 generated at least one docked
pose that was scored −90 or lower by PLANTS, and were taken into the four hit selection
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routes (A–D, Figure 5). Using the same docking protocol for the 47 published TbrPDEB1
inhibitors yielded docking poses with PLANTS scores below −90 for 16 inhibitors, of which
13 are expected to address the P-pocket2 (Table S5 in Supporting Information). In selection
routes A and B, the IFPs generated from the docked poses were compared to those of the
reference ligands 1 (IFP1, Figure 5) and 2 (IFP2, Figure 5), respectively. The putative
binding modes of 1 (Figure 6A) and 2 (Figure 6B) were used to calculate the reference IFPs,
IFP1 and IFP2, respectively. The binding modes of 1 and 2 were explored through
molecular docking and were similar to those of close analogues proposed previously.2 The
tridentate interaction between the putative binding mode of 1 and Q874 is a feature that has
also been proposed for compound 5.9 In order to retrieve hits able to form at least two
hydrogen bonds with Q874, a filter (GLN Filter) was applied in route A. This retrieved
docking poses in which ligands formed hydrogen bonds with each side chain amide
hydrogen atom of Q874. Reference compound 2 was predicted to penetrate deeply into the
P-pocket, forming a hydrogen bond between the tetrazole ring and Y845. Compounds in
route C were selected according to their ranking by PLANTS. Route D included ligands that
scored well in PLANTS and appeared to fit the pocket well, but were outside the top 50 of
each route. All routes involved steps to maintain structural diversity from the other
compounds being selected for testing (MACCS similarity filter applied) and also to ensure
that hits would be novel from the 47 published TbrPDEB1 inhibitors (Table S1 and Table S5
in Supporting Information, ECFP424 and ROCS23 similarity scoring used).
From the docking results, 29 compounds were selected according to the selection routes A–
D shown in Figure 5. Of the 29 purchased compounds, 6 were found to inhibit TbrPDEB1
with IC50 values below 100 μM, of which 3 had IC50 values of around 10 μM (Table 2),
resulting in an overall hit rate of 21%. While the number of compounds tested is low, these
results support the use of IFP similarity scores (routes A–B) to improve hit selection
compared with the use of docking scores (route C) or visual inspection (route D) alone.
Routes A and B together yielded 5 experimentally confirmed hits (38% of the 13 selected
compounds), while 1 new TbrPDEB1 ligand was discovered via route C (12.5% of the 8
selected compounds), and D did not give any hit at all (of the 8 selected compounds).
Interestingly, routes C–D result in a higher hit rate of experimentally confirmed hPDE4
inhibitors than routes A–B (Supporting Information Table S1). This indicates that the
interactions specific to TbrPDEB1, implemented in the IFP similarity scoring procedure, are
essential for the identification of hits with TbrPDEB1 activity.
Reference compound 1 was predicted to form a tridentate interaction with Q874 (Figure
6A). This interaction profile aids the selection of compounds which fill the entrance of the
P-pocket and strengthens the interactions with Q874. The virtual screening hit 17, selected
using route A, was found to be out of stock at its supplier and the close analogue 16 was
chosen to replace it (Figure 6C). The compounds adopt the same binding mode in docking
studies, and thus the discovery of the active hit can be attributed to the success of the virtual
screening method. Compound 19, selected using route B, forms a hydrogen bond with Y845
seen in the binding mode of 2 (Figure 6B, D). Protein-ligand interactions between the
docked poses and a select group of pocket residues are described in bit string form in Figure
6E. The IFP Tanimoto scores compare all interactions between the reference ligand and the
protein to those between the docked poses of the screened compounds and the protein. The
entire pocket is used for the comparison to allow subtle interaction motifs to be picked up
which may be missed during visual inspection. Although numbers are too low to for
conformation, the higher hit rate of routes A and B suggests that the combined use of these
IFP Tanimoto scores and the PLANTS docking scores aids hit selection.
Occupation of the P-pocket was implemented as a selectivity driver in the virtual screening
and the corresponding selection routes A–B indeed yielded more TbrPDEB1 hits than the
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other selection routes (Figure 5, Table 2). Nevertheless, all confirmed TbrPDEB1 hits still
showed inhibition of hPDE4 with selectivity ratios of 0.4 – 4 (TbrPDEB1 IC50 over hPDE4
IC50), suggesting adaptation of the binding mode or induced fit to accommodate the ligands
in hPDE4. These selectivity ratios are a clear improvement over published TbrPDEB1
inhibitors, all of which (including compounds 1 and 2) have significant selectivity against at
least one of the human PDEs.1–2, 5–6, 10–11, 25 While the molecular docking simulations
suggest that the virtual screening hits and compounds 1 and 2 target the P-pocket of
TbrPDEB1 (Figure 6), this has yet to be verified structurally or using site directed
mutagenesis.
Prospective structure-based virtual screening studies on PDE targets remain scarce, with just
three reported in literature. In one study, a virtual screening for TcrPDEC inhibitors used a
library of 60,000 compounds,13 and a homology model built with a hPDE4B crystal
structure (1XMY) as a reference. Following docking, hits were filtered on drug like
properties, rescored using consensus scoring, analyzed for hydrogen bonding and
hydrophobic profiles, and visually inspected, resulting in the selection of 25 compounds for
pharmacological screening, 10 of which were TcrPDEC inhibitors with low micromolar
IC50 values.13 A hPDE3 study has also been reported in which 3,000 compounds, out of an
initial library of 113,000, were docked, and 80 were screened for enzymatic inhibition,
resulting in one low micromolar hit.14 Finally in a virtual screening on hPDE5 that began
with a library of 5 million compounds, an iterative process of filtering, docking and
pharmacological screening was used to retrieve 22 low micromolar and 12 submicromolar
inhibitors from a set of 196 tested compounds.15 The current study provides further evidence
for the utility of structure-based virtual screening in the discovery of PDE inhibitors. Even
though only an unliganded TbrPDEB1 structure was available, a customized scoring method
has been able to identify hits with improved selectivity as starting points for further
optimization. With over 150 crystal structures now available, the time is ripe for the
application of structure-based virtual screening to the discovery of novel human and parasite
PDE inhibitors.
CONCLUSIONS
The crystal structure of the catalytic domain of TbrPDEB1 was resolved at a resolution of
1.65 Å. The resolved crystal structure corroborates the existence of the parasite PDE-
specific P-pocket and represents a significant step forward for HAT-directed drug discovery
efforts. In the present study the unliganded structure has been used to identify TbrPDEB1
inhibitors by virtual screening. Although the new hits show only moderate to low
micromolar inhibition, each of them represents a novel scaffold and thereby a new potential
starting point for future drug discovery efforts on TbrPDEB1. The combined use of docking
scores and protein-ligand interaction fingerprints (IFPs) has allowed us to identify novel
TbrPDEB1 inhibitors. It is noted that the new experimentally confirmed TbrPDEB1 hits are
equipotent for TbrPDEB1 and hPDE4 in contrast to previously published TbrPDEB1
inhibitors, all of which have significant selectivity against at least one of the human PDEs.
This suggests that targeting the P-pocket in structure-based studies might indeed be a way
forward to the design and discovery of selective TbrPDEB1 inhibitors.
EXPERIMENTAL SECTION
Subcloning, expression, purification and crystallization of catalytic domain tbrPDEB1
The catalytic domain of TbrPDEB1 with amino acids 576–918 was amplified by PCR and
subcloned into the expression vector pET28a. The resultant plasmid pET-PDEB1 was
transferred into E. coli strain BL21 (Codonplus) for overexpression. The E. coli cell carrying
pET-PDEB1 was grown in LB medium at 37°C to absorption of A600 = 0.7 and then 0.1
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mM isopropyl β-D-thiogalactopyranoside was added to induce the overexpression at 15°C
for 24 hours. Recombinant PDEB1 was passed through a Ni-NTA column (Qiagen),
subjected to the thrombin cleavage, and further purified by the columns of Q-Sepharose and
Sephacryl S300 (Amersham Biosciences). A typical purification yielded over 10 mg
TbrPDEB1 with a purity >95% from a 2-liter cell culture.
Crystallization, structure determination and analysis of TbrPDEB1
The catalytic domain of the unliganded TbrPDEB1 (576–918) was crystallized by vapor
diffusion against a well buffer of 20% PEG3350, 0.4 M Na formate, 0.2 M guanidine, 0.1 M
MES pH 6.5 at 4°C. Diffraction data was collected on a beamline X29 at the Brookhaven
National Laboratory and processed by program HKL2000.26 The crystal of the unliganded
TbrPDEB1 has the space group C2 with cell dimensions of a = 115.0, b = 115.3, c = 68.5 Å,
and β = 108.1°. The 6.8-fold redundant measurement yielded R-merge of 0.059 for 92,150
unique reflections that represent 90.9% completeness to 1.65 Å resolution. The structure of
TbrPDEB1 was solved by molecular replacement program AMoRe,27 using the LmjPDEB1
structure as the initial model.12 The structure was rebuilt by the program O28 and refined by
the program CNS29 to R-factor/R-free of 0.205/0.224. Secondary structure determination
was performed using DSSP.30–32 Sequence alignment of the TbrPDEB1, LmjPDEB1,
TcrPDEC and hPDE4B catalytic domains was performed using ClustalW 2.1.33 Structural
superposition of the Cα atoms of TbrPDEB1 (4I15, chain A) with LmjPDEB1 (2R8Q, chain
A), TcrPDEC (3V94, chain A) and hPDE4B (1XM4, chain B) was performed with MOE
(Molecular Operating Environment version 2011.10).19 All structures were visualized using
Pymol 1.5.0.3.34
Database preparation for virtual screening
The databases of 14 suppliers (Table S3 in Supporting Information) containing 7.5 million
unique structures in total were downloaded from ZINC (17-06-2011).23 The structures were
passed through Openeye’s filter (version 2.1.1) in smiles format.35 Those with physical
chemical properties that fell within all of the following ranges were kept for further
processing: heavy atoms 20 – 30, ring systems 3 – 6, rotatable bonds 2 – 8, TPSA 50 – 90,
LogP −10 – 4, hydrogen bond acceptors 3 – 5, hydrogen bond donors 0 – 2, and charge −1 –
+1. Note that due to a difference in filter definition, ring systems, rather than rings, were
counted, leading to unintended filtering of the database (Figure S1 in Supporting
Information). The structures then passed through ChemAxon’s Jcsearch (version 5.4.1.1)
and those compounds with at least one of the following features were kept for further
processing: aromatic rings containing at least one nitrogen atom, conjugated rings with
carbonyl or imines, or phenols (Figure S2 in Supporting Information). The remaining
structures were prepared for docking by converting them from isomeric SMILES to mol2
format using Molecular Networks’ Corina (version 3.46).36
Protein preparation for virtual screening
The A chain of the TbrPDEB1 crystal structure was prepared for docking using MOE
(version 2011.10) by adding and minimizing the hydrogen atoms using the protonate 3D
function.19 The water molecules and metal ions were removed from the structure. The
pocket of protein was defined for use during the processing of the docking results and both
the protein and pocket were utilized in mol2 format.
Virtual screening
Each of the filtered ZINC23 compounds was docked 25 times using the speed 2 setting of
PLANTS and the chemPLP scoring function.20 After docking, the protein-ligand interaction
fingerprint (IFP)21–22 of each docking pose was calculated and compared to the IFPs of the
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reference compounds 1 and 2, resulting in a Tanimoto similarity score. A filter was applied
to the generated docking poses so that only those which scored ≤−90 were kept for further
processing. In route A, a filter required docked poses to form hydrogen bonds with both
hydrogen atoms of the side chain amide of Q874 before an IFP1 score cutoff of ≥0.75 was
applied. In route B, an IFP2 score cutoff of ≥0.75 was applied. The results from routes A–C
were ranked by docking scores and the top 50 diverse structures were selected based on
MACCS clustering in MOE19 using a Tanimoto similarity cutoff of 70%. The selected
compounds were then visually inspected and compared to known TbrPDEB1 inhibitors
(Table S1 and Table S5 in Supporting Information, ROCS: Comboscore ≤1.4 out of 237;
ECFP-4: score ≤0.4 out of 138), and checked for supplier availability or close analogue
availability if the compounds were unavailable. A total of 21 compounds were selected for
purchase from this set. In addition, 8 compounds that fell outside the criteria of routes A–C
were selected for purchase in route D on basis of visual inspection of a larger set of docking
poses. For route D, binding modes of the top 300 diverse compounds from each of the routes
A–C (excluding the top 50 used in those routes) were visually inspected. Docking poses
were selected based on the following criteria: i) occupation of the P-pocket,2 ii) hydrogen
bonding with Q874,17 iii) occupation of the hydrophobic clamp by an aromatic moiety,17 iv)
hydrogen bonding to Y845 or π-stacking to F844.2
IFP processing
The IFPs were defined using 7 protein-ligand interaction types between residues of the
pocket and the ligand as described previously.21 The interaction types used were: 1. Apolar;
2. Aromatic face-to-face; 3. Aromatic edge-to-face; 4. H-bond donor (protein) – H-bond
acceptor (ligand); 5. H-bond donor (ligand) – H-bond acceptor (protein); 6. Ionic interaction
positive (protein) – negative (ligand); 7. Ionic interaction positive (ligand) – negative
(protein). The pocket was defined by 40 residues for IFP1 calculations, Y668, H669, H673,
H709, D710, H713, L716, N717, N718, S719, T783, M785, A786, G789, D822, I823,
N825, V826, S833, W836, A837, V840, T841, E843, F844, L859, P860, M861, F862,
N867, M868, E869, G873, Q874, G876, F877, I878, F880, V881, A882 and 42 residues for
IFP2 calculations with the addition of Y845 and L870. For each docking pose, the
coordinates of pocket including the rotated hydroxyl hydrogen atoms were recorded and
used to define the IFP. Standard IFP scoring parameters and a Tanimoto coefficient
measuring IFP similarity with the reference molecule, were used to filter and rank docking
poses. The reference IFP strings are available as Supporting Information.
Compounds selected by virtual screening
The compounds selected by virtual screening were purchased from available screening
collections of two vendors: Enamine (www.enamine.com) and Vitas-M
(www.vitasmlab.com). The purities of all 29 purchased compounds were verified by liquid
chromatography-mass spectrometry (LC-MS), all experimentally validated hits had a purity
of 95% or higher (Table S2 in Supporting Information).
Inhibition assay
The scintillation proximity assay (SPA) described by De Koning et al., was followed exactly
for the determination of full length PDE activities.2, 6 The assay was used to determine IC50
values of purchased compounds on TbrPDEB1 and hPDE4B using a cAMP substrate
concentration of 0.5 μM. The PDE was collected by sonification of supernatants of PDE
overexpressing Sf21 cells. The PDE activity of the enzyme was determined in at least
duplicates by published procedures.39–40 Enzyme concentrations were set so that <20% of
the cAMP was consumed during the assay. Blank values were measured in the presence of
denatured protein and always resulted in <2% of the total radioactivity. For inhibitors, which
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did not reach 100% inhibition at the highest concentration measured, inhibition curves were
fitted to derive IC50 values with the assumption that the inhibition curves plateau at 100%
inhibition, since the inhibitors are expected to bind competitively to the PDE substrate
binding pocket.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank beamline X29 at NSLS for collection of the diffraction data. This work was partially supported by NIH
GM59791 to HK and was performed under the framework of the Top Institute Pharma project “Phosphodiesterase
Inhibitors for Neglected Tropical Diseases” (T4-302) with partners VU University Amsterdam, University of Bern,
The Royal Tropical Institute (KIT), Mercachem BV, Nycomed (a Takeda company), IOTA Pharmaceuticals Ltd.,
Drugs for Neglected Diseases initiative (DNDi), and TI Pharma. Netherlands Organization for Scientific Research
(NWO) is acknowledged for financial support through a VENI grant (700.59.408 to C. de G.)
ABBREVIATIONS USED
HAT Human African trypanosomiasis
IFP Protein-ligand interaction fingerprint
LmjPDEB1 Leishmania major phosphodiesterase B1
TbrPDEA Trypanosoma brucei phosphodiesterase A
TbrPDEB1 Trypanosoma brucei phosphodiesterase B1
TbrPDEB2 Trypanosoma brucei phosphodiesterase B2
TbrPDEC Trypanosoma brucei phosphodiesterase C
TbrPDED Trypanosoma brucei phosphodiesterase D
TcrPDEC Trypanosoma cruzi phosphodiesterase C
SPA scintillation proximity assay
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Previously reported TbrPDEB1 inhibitors, 1, 2, 3, 4 and 5, showing the IC50 values of the
compounds against TbrPDEB1 in μM.
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(A) An overview of the X-ray crystal structure of TbrPDEB1, helices are colored yellow and
labeled where visible, 310-helices are shown in fuchsia, and loops are shown in purple. The
metal ions magnesium (lime) and zinc (gray) are shown. (B) A superposition of crystal
structures of TbrPDEB1 (yellow), LmjPDEB1-IBMX (2R8Q in blue)12, TcrPDEC-WYQ16
(3V94 in green)4, and a crystal structure of hPDE4B-piclamilast (1XM4 in magenta).17
Close-ups of the region between Q874 on H15 and the M-loop are shown in: (C)
TbrPDEB1; (D) LmjPDEB1; (E) TcrPDEC; and (F) hPDE4B.
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Sequence alignment between TbrPDEB1, LmjPDEB1, TcrPDEC and hPDE4B. The bars
indicate secondary structure features, α-helices are shown in yellow and 310-helices are
shown in fuchsia. Residues of the substrate binding pocket are shown in red. The helix
numbers of TbrPDEB1 are indicated above the sequence, as are the H-loop and the M-loop.
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The substrate binding pocket of TbrPDEB1 (chain A) with the carbon atoms colored by B-
factor, the range is shown on a color bar. Two water networks (red spheres) are shown with
hydrogen bonds (gray dashes), one of which surrounds the invariant glutamine (Q874) and a
second, which surrounds the metal ions. Pocket residues are shown as sticks and labeled
where visible. The P-pocket is shown as a gray surface.
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Overview of the compound selection process. (I) A selection of unique structures retrieved
from a select set of 14 suppliers in the ZINC library. (II) Structures that pass a set of
physical chemical filters and contain a substructure moiety able to interact with Q874 and
the hydrophobic clamp. (III) Structures that have at least one docking pose that scored −90
or lower in PLANTS.22 With the GLN Filter only docking poses that form hydrogen bonds
with both Q874 side chain amide hydrogen atoms were selected. The IFP1 score is the
Tanimoto score between the IFP of each docked pose and the IFP of the putative binding
mode of 1, a cut-off of 0.75 was applied.22 (B) The IFP2 score was calculated using the
putative binding mode of 2 as the reference and those docked poses scoring 0.75 and above
were kept. Compounds from routes A, B, and C were then ranked by PLANTS scores before
being filtered for diversity. The top 50 compounds from routes A, B, C and D were selected
and 9, 4, 8 and 8 compounds were selected respectively, according to diversity, availability
and visual inspection of the docking poses. Of the compounds selected using routes A, B, C
and D; 3, 2, 1 and 0 compounds, respectively, were active.
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Panels A–D show the TbrPDEB1 backbone as a gold ribbon, key pocket residues and
ligands as sticks, metal atoms as spheres, and the P-pocket as a gray transparent surface. The
modeled binding poses of compounds 1 (green, panel A) and 2 (red, panel B) are similar to
those proposed previously for close analogues,2 and are used as references for the
calculation Tanimoto scores based on IFP similarity.21–22 Compounds 16 (magenta) and 17
(cyan) (panel C) show a similar binding mode to compound 1, while compound 19 (panel D)
shows a greater similarity to the binding mode of compound 2. Bit strings are used in IFPs
to indicate the absence (0) or presence (1) of an interaction type between the ligand and each
residue, as shown in panel E for compounds 2, 4, 16, 17 and 18. A sequence of seven bits is
used for each residue and the position of each bit determines the interaction type (see
legend). For the sake of clarity, only the bit strings of V840, T841, F844, Y845, Q874 and
F877 are shown, of the 42 pocket residues.
Protein-ligand interactions described in IFPs are encoded as seven bits per residue as
follows: 1. Apolar; 2. Aromatic face-to-face; 3. Aromatic edge-to-face; 4. H-bond donor
(protein) – H-bond acceptor (ligand); 5. H-bond donor (ligand) – H-bond acceptor (protein);
6. Ionic interaction positive (protein) – negative (ligand); 7. Ionic interaction positive
(ligand) – negative (protein). An additional H-bond bit was included for GLN874 (GLN
Filter): * H-bond formation with both polar hydrogen atoms of the Q874 side-chain.
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Table 1
Statistics on diffraction data and structural refinement.
Data collection
 Space group C2 (C121)
 Unit cell (a, b, c, Å) 115.01, 115.34, 68.51, 90, 108.1, 90
 Resolution (Å) 30.00 – 1.65
 Unique reflections 92,150
 Fold of redundancy 6.8
 Completeness (%) 90.9 (54.8a)
 Average I/δ 13.2 (2.7a)





 RMS deviation for bond (Å) 0.005
 Angle (degree) 1.06
Average B-factor (Å2)
 Protein(# of atoms) 31.8 (5272)
 Waters(# of atoms) 36.7 (404)
 Zn(# of atoms) 26.8 (2)
 Mg(# of atoms) 26.0 (2)
 Ramachandran plot statistics (%) as defined in CCP4
 Most favored regions 91.7
 Additionally allowed regions 7.7
 Generously allowed regions 0.7
 Disallowed regions 0.0
a
For the resolution shell of 1.71–1.65 Å.
b
Reflections omitted for calculation of R-free.
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